Clinical Trial Update: Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing ongoing evaluation of BRII-835 (VIR-2218) in combination with PEG-IFNα for chronic hepatitis B infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• BRII-835 (VIR-2218) (BRII-835)
• PEG-IFNα (pegylated interferon alfa)

Snippet

Sponsor: Brii Biosciences Limited | Conditions: Chronic Hepatitis B Virus Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING